Symptom Experience After Discontinuing Use of Estrogen Plus Progestin

Abstract
Recommended guidelines and prescribing practices for menopausal hormone therapy (MHT) have changed significantly1,2 since publication of the Women's Health Initiative (WHI) estrogen plus progestin (E + P) trial findings that the overall health risks of taking conjugated equine estrogens and medroxyprogesterone acetate for disease prevention exceed the benefits.3 Management of vasomotor and vaginal dryness symptoms remains the cornerstone of opinion in favor of MHT use. Women frequently cite relief from vasomotor symptoms4,5 and improvement in well-being as reasons for starting or continuing MHT.6,7